HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermablend

This article was originally published in The Rose Sheet

Executive Summary

Reflections extensions include Concealer, Self Tanner and Face and Body Bronzer formulated with same patented Melasyn technology as foundation, skin care line, L'Oreal division says. Debuting in April in department stores, concealer will retail for $18, while bronzer and self-tanner will cost $22 each. Melasyn technology, developed by John Pawelek, PhD, Yale University, uses skin's melanin, natural light to give "glow and appearance of perfectly matched skin tone," company claims. Reflections originally debuted last July targeted to women over 40 (1"The Rose Sheet" July 17, 2000, p. 5)

You may also be interested in...



Dermablend Essential Benefits Targets Older Audience, Carson Says

Dermablend's new concealment makeup and skin care line will target older consumers under the brand name Essential Benefits. The approximately 50-SKU will undergo a slow rollout, initially bowing in August in 75-100 doors including Lord & Taylor and Nordstrom with additional distribution slated for 2001.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
UsernamePublicRestriction

Register

RS009148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel